21.01.2022 • News

Barentz Acquires Assets from Mexico’s Chemcel

Dutch-based global distributor Barentz International, specializing in life science ingredients, has acquired unspecified assets of Chemcel, a distributor of specialty ingredients for the Mexican pharmaceutical and nutrition markets. Financial terms were not disclosed.

With its technical sales team, in-house formulation capabilities and a product portfolio focused on specialty excipients, Barentz said Chemcel provides the company with a “natural platform“ to further expand into the Mexican market, where it will operate in future as Barentz Mexico. The team will continue to be headed by Chemcel managing director and shareholder Julio Rendon, and the headquarters will remain in Mexico City.

Beyond strengthening the European company’s existing presence in Latin America, the buy also provides an opportunity for further expansion through strategic principal relationships, Barentz said, noting that the gain of a in-house laboratory & technical service team dedicated to the pharmaceutical industry will complement its to global network of more than 30 laboratories across four continents.

Barentz CEO Hidde van der Wal said Mexico has long represented a strategic market for the Hoofddorp-headquartered distributor, and Chemcel is an ideal fit with its commercial strategy and entrepreneurial culture. In return, Rendon said the Mexican firm sees a “tremendous opportunity” to benefit from Barentz’ global infrastructure and relationships.

Author: Dede Williams, Freelance Journalist

(c) Myriam Zilles
(c) Myriam Zilles

Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.